Pancreas and the seventh cavalry: vaccines.

As you may have read in the previous article, progress in pancreatic cancer research has been slow. However, promising advances are beginning to emerge, such as KRAS inhibitors like daraxonrasib—innovative treatments you can learn more about in our earlier piece.

At One Shôt, we invite you to read the following article to better understand the importance—and the potential revolution—of cancer vaccines. While inhibitors, rooted in more traditional medical approaches, are proving effective, vaccines represent a truly transformative shift. Presenting both sets of data and conclusions is essential to help you appreciate the progress being made and the importance of continuing research in vaccines and personalized molecular medicine.

From One Shôt, we encourage you to keep reading our articles—and to keep fighting.

Today, we want to show how vaccine development is reaching pancreatic cancer research with high expectations.

A personalized pancreatic cancer vaccine shows promising long-term results.

A new approach based on personalized messenger RNA (mRNA) vaccines could change how pancreatic cancer is treated—one of the most aggressive cancers with the poorest prognosis. This is highlighted in an article published by the Memorial Sloan Kettering Cancer Center (MSK), written by Jim Stallard on April 19, 2026, summarizing early clinical trial results with particularly encouraging data.

How this new vaccine works.

Unlike traditional vaccines—which prevent infections—this is a therapeutic vaccine. It does not prevent cancer from developing, but instead helps the body fight it and reduces the risk of it coming back after treatment.

The process is highly personalized. First, doctors surgically remove the patient’s tumor and analyze its DNA to identify specific mutations. Based on that information, a unique vaccine is created for each individual using mRNA technology.

This vaccine “teaches” the immune system to recognize abnormal tumor proteins known as neoantigens. Once trained, the body produces immune cells—especially T cells—that can locate and destroy cancer cells.

Results that stand out.

The phase 1 clinical trial included 16 patients who received the vaccine after surgery, along with chemotherapy and immunotherapy.

The results show a clear difference:

• In 8 patients, the vaccine successfully activated the immune system.

• Of those, 7 patients (87.5%) were still alive between 4 and 6 years after treatment.

• By contrast, among patients who did not respond, only 25% were still alive, with a median survival of 3.4 years.

These figures stand out when compared to the overall five-year survival rate for pancreatic cancer, which is about 13%, according to the American Cancer Society.

The study’s lead investigator, Dr. Vinod Balachandran, emphasized that these results suggest “vaccines can meaningfully stimulate the immune system in some patients and help keep them disease-free for years.”

Why this approach is different.

One of the biggest challenges in cancer treatment is that tumor cells originate from the body itself, so the immune system does not always recognize them as a threat. This vaccine overcomes that problem by specifically “flagging” what the immune system should attack.

It is also designed to create a long-lasting response. In the study, vaccine-activated immune cells remained in the body for up to six years, suggesting durable immune memory.

New research directions.

Based on these results, a global phase 2 clinical trial is already underway to confirm the vaccine’s effectiveness in a larger group of patients.

At the same time, researchers are developing “off-the-shelf” vaccines targeting common mutations such as KRAS, which are present in many pancreatic cancers. These could be produced at scale and administered without full personalization.

A Promising Path—Still in Development.

While the results are encouraging, researchers stress that this is still an early-stage study. Not all patients responded to the treatment, and more work is needed to improve its effectiveness and expand it to a broader population.

Even so, this approach represents a major shift: instead of directly attacking the tumor with drugs or chemotherapy, the goal is to turn the patient’s own immune system into the primary weapon against cancer.

As Dr. Balachandran concludes, the aim is to harness the body’s natural defenses as a “secret weapon” against one of the most difficult diseases to treat.

Source: Memorial Sloan Kettering Cancer Center

Author: Jim Stallard

Date: April 19, 2026

One Shôt

The IMpatients